

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



	I							
Section 1.	Identifying Inform	ation						
1. Given Name (First Name) Rupert		2. Surname (Las Lees	t Name)		3. Date 22-January-2017			
4. Are you the cor	responding author?	✓ Yes No						
5. Manuscript Title 2017-2018 ECCC	e Annual Disclosure of P	otential Conflict	s of Interest					
6. Manuscript Ide	ntifying Number (if you kn	ow it)						
Continue 2								
Section 2.	The Work Under Co	onsideration f	or Publication					
any aspect of the s statistical analysis, Are there any rel	ubmitted work (including	but not limited to			ent, commercial, private foundation, etc.) udy design, manuscript preparation,) for		
Section 3.	Relevant financial	activities outs	ide the submitted	work.				
of compensation) with entities as descri	bed in the instru	ctions. Use one line fo	or each er	cial relationships (regardless of amou ntity; add as many lines as you need b e 36 months prior to publication.			
•	evant conflicts of intere		No					
If yes, please fill o	out the appropriate info	rmation below.						
Name of Entity		Grant? Perso	onal Non-Financial Support?	Other?	Comments			
/ifor Pharma					Professor A J Lobo is an advisory board member. Sponsorship for conference attendance for Professor A J Lobo			
MSD					Professor A J Lobo is an advisory board member			
Pfizer					Professor A J Lobo is an advisory board member			
Abbvie					Professor A J Lobo is an advisory board member			



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
akeda		✓			Professor A J Lobo is an advisory board member. Speaker fees also paid to Professor A J Lobo.
r Falk		✓			Professor A J Lobo is an advisory board member
anssen		✓			Sponsorship for conference attendance for Professor A J Lobo. Speaker fees also paid to Professor A J Lobo.
hield Pharma		√			Speaker fees for Professor A J Lobo.
ilotts Pharma		√			Sponsorship for conference attendance for Professor A J Lobo
Patent?	Pending?	d? Licens	ed? Royalties?	License	ee? Comments
BD-RAPID	V				Application for a patent is still under consideration, with no application having been made at this point in time.
Section 5. Relationship	os not covered	above			
Are there other relationships or a potentially influencing, what you				nfluence	d, or that give the appearance of
Yes, the following relationsh No other relationships/cond	•				
At the time of manuscript accep					



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Mr Lees, Dr Brookes, Dr Rowse, Professor Norman, Dr Narula have no disclosures. Professor A J Lobo reports personal fees from Vifor Pharma, personal fees from MSD, personal fees from Pfizer, personal fees from Abbvie, personal fees from Takeda, personal fees from Dr Falk, personal fees from Janssen, personal fees from Shield Pharma, personal fees from Tilotts Pharma, outside the submitted work; In addition, Mr. Lees has a patent IBD-RAPID pending.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.